DaVita (DVA)
(Delayed Data from NYSE)
$163.08 USD
+0.82 (0.51%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $162.00 -1.08 (-0.66%) 5:24 PM ET
1-Strong Buy of 5 1
A Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$163.08 USD
+0.82 (0.51%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $162.00 -1.08 (-0.66%) 5:24 PM ET
1-Strong Buy of 5 1
A Value C Growth D Momentum B VGM
Zacks News
New Strong Buy Stocks for May 6th
by Zacks Equity Research
ROOT, SMCI, PPC, DFH and DVA have been added to the Zacks Rank #1 (Strong Buy) List on May 6, 2024.
Best Value Stocks to Buy for May 6th
by Zacks Equity Research
DFH, DVA and BDC made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 6, 2024.
DaVita (DVA) Q1 Earnings & Revenues Top Estimates, Margins Up
by Zacks Equity Research
DaVita's (DVA) robust segmental revenues drive its first-quarter performance.
DaVita HealthCare (DVA) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 21.43% and 2.01%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Strength in Kidney Care Likely to Aid DaVita's (DVA) Q1 Earnings
by Zacks Equity Research
Improvement in revenue per treatment and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the first quarter.
What's in Store for These 5 Medical Device Stocks in Q1 Earnings?
by Zacks Equity Research
Here is a sneak peek into how five medical device stocks, BDX, BAX, XRAY, CAH and DVA, might fare in their quarterly results slated to be released tomorrow.
DaVita HealthCare (DVA) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
DaVita HealthCare (DVA) concluded the recent trading session at $132.77, signifying a +0.02% move from its prior day's close.
Amedisys (AMED) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 1.98% and 1.21%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Philips' (PHG) Zenition 30 to Boost Image-Guided Surgeries
by Zacks Equity Research
Philips (PHG) announces the FDA clearance for its Zenition 30 mobile C-arm, which is intended to aid in image-guided procedures at a relatively affordable cost.
Is Trending Stock DaVita Inc. (DVA) a Buy Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to DaVita HealthCare (DVA). This makes it worthwhile to examine what the stock has in store.
Neogen (NEOG) Inks Genomics Deal to Aid in Food Tracing
by Zacks Equity Research
Neogen (NEOG) announces a genomics relationship with Performance Food Group to trace food products back to their origin using PathProven food trace technology.
DaVita HealthCare (DVA) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
DaVita HealthCare (DVA) closed at $127.82 in the latest trading session, marking a +1.36% move from the prior day.
Reasons Why You Should Retain Masimo (MASI) Stock for Now
by Zacks Equity Research
Masimo's (MASI) R&D activities raise optimism about the stock.
CVRx's (CVRX) Latest Data Favors Barostim's Long-Term Benefits
by Zacks Equity Research
CVRx's (CVRX) announcement of the availability of additional data supporting the long-term benefits of Barostim is likely to lead to improved patient care.
GE HealthCare's (GEHC) Voluson to Aid Women's Health Imaging
by Zacks Equity Research
GE HealthCare (GEHC) announces its latest AI-powered Voluson Signature 20 and 18 ultrasound systems, which are likely to provide effective and efficient care for conditions impacting women's health.
AtriCure's (ATRC) cryoSPHERE+ Probe to Aid in Pain Management
by Zacks Equity Research
AtriCure (ATRC) unveils its cryoSPHERE+ cryoablation probe, which is intended to reduce freeze times and aid in postoperative pain management.
Intuitive Surgical (ISRG) Q1 Earnings Beat, Procedures Robust
by Zacks Equity Research
Intuitive Surgical's (ISRG) first-quarter results reflect a healthy demand for procedures. Higher pricing boosts procedure sales. An improvement in margins buoys well.
DaVita HealthCare (DVA) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
The latest trading day saw DaVita HealthCare (DVA) settling at $126.11, representing a -1.2% change from its previous close.
Outset Medical (OM) Inks Multi-Year Deal to Boost Home Dialysis
by Zacks Equity Research
Outset Medical's (OM) latest agreement is likely to provide patients and caregivers access to innovative home dialysis with the Tablo Hemodialysis System.
Why You Should Add Inspire Medical (INSP) to Your Portfolio
by Zacks Equity Research
Inspire Medical's (INSP) focus on R&D raises optimism about the stock.
Here's Why You Should Retain Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Medtronic (MDT) due to the strength of its Neurosurgery and Cardiovascular portfolios.
IceCure Medical (ICCM) Submits Final Cryoablation Data to FDA
by Zacks Equity Research
IceCure Medical (ICCM) submits final ICE data along with multiple sub-analysis to the FDA seeking approval for marketing authorization for treating early-stage breast cancer.
Here's Why DaVita HealthCare (DVA) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now
by Zacks Equity Research
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
PacBio (PACB) Preliminary Q1 Revenues Dampened by Purchase Delays
by Zacks Equity Research
PacBio's (PACB) revenue growth in the first quarter is likely to have been hampered by an increasing number of customers delaying instrument purchases and softness in consumable shipments.